Tokyo Tape
Sign in
← Terumo

Quarterly report · Q2

4543.TEDINET S100S9UJ
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥443.9bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥228.6bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥403.3bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥206.0bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥66.5bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥36.8bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥56.0bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥25.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥66.4bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥36.6bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥54.6bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥25.0bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥50.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥27.5bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥50.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥27.5bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥1.75Tat 2023-09-30Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.66Tat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥487.4bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.26Tat 2023-09-30Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.17Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.26Tat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.17Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥187.3bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥212.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥53.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥60.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥36.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥31.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥30.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥37.9bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥67.272023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥36.992023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥1192022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥53.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.752022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥67.242023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥36.972023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥118.952022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥53.352022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.742022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio70.6%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥119m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥84.1bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥10.6bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥265.7bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥57.6bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥94.0bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥8.3bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥443.8bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥76.6bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥124m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥275m
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥74.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥9.1bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥235.4bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥52.9bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥93.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥403.2bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥70.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 690
ItemContextValueUnit
Other non current liabilities ncl IFRSCurrentQuarterInstant10002000000JPY
Non current labilities IFRSPrior1YearInstant273161000000JPY
Non current labilities IFRSCurrentQuarterInstant127793000000JPY
Liabilities IFRSPrior1YearInstant491162000000JPY
Liabilities IFRSCurrentQuarterInstant487400000000JPY
Share capital IFRSPrior1YearInstant38716000000JPY
Share capital IFRSCurrentQuarterInstant38716000000JPY
Capital surplus IFRSPrior1YearInstant51759000000JPY
Capital surplus IFRSCurrentQuarterInstant51631000000JPY
Treasury shares IFRSPrior1YearInstant-11539000000JPY
Treasury shares IFRSCurrentQuarterInstant-11182000000JPY
Retained earnings IFRSPrior1YearInstant874272000000JPY
Retained earnings IFRSCurrentQuarterInstant908810000000JPY
Other components of equity IFRSPrior1YearInstant157855000000JPY
Other components of equity IFRSCurrentQuarterInstant273019000000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant1111063000000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant1260996000000JPY
Equity IFRSPrior1YearInstant1111063000000JPY
Equity IFRSCurrentQuarterInstant1260996000000JPY
Liabilities and equity IFRSPrior1YearInstant1602225000000JPY
Liabilities and equity IFRSCurrentQuarterInstant1748396000000JPY
Revenue IFRSPrior1YTDDuration403316000000JPY
Revenue IFRSCurrentYTDDuration443874000000JPY
Cost of sales IFRSPrior1YTDDuration196323000000JPY
Cost of sales IFRSCurrentYTDDuration215619000000JPY
Gross profit IFRSPrior1YTDDuration206992000000JPY
Gross profit IFRSCurrentYTDDuration228255000000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration146770000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration163254000000JPY
Other income IFRSPrior1YTDDuration3277000000JPY
Other income IFRSCurrentYTDDuration3149000000JPY
Other expenses IFRSPrior1YTDDuration7522000000JPY
Other expenses IFRSCurrentYTDDuration1657000000JPY
Operating profit loss IFRSPrior1YTDDuration55977000000JPY
Operating profit loss IFRSCurrentYTDDuration66492000000JPY
Finance income IFRSPrior1YTDDuration929000000JPY
Finance income IFRSCurrentYTDDuration1324000000JPY
Finance costs IFRSPrior1YTDDuration1978000000JPY
Finance costs IFRSCurrentYTDDuration1489000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-303000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration100000000JPY
Profit loss before tax IFRSPrior1YTDDuration54624000000JPY
Profit loss before tax IFRSCurrentYTDDuration66428000000JPY
Income tax expense IFRSPrior1YTDDuration14303000000JPY
Income tax expense IFRSCurrentYTDDuration16336000000JPY
Profit loss IFRSPrior1YTDDuration40321000000JPY
Profit loss IFRSCurrentYTDDuration50092000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration40321000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration50092000000JPY
Profit loss IFRSPrior1YTDDuration40321000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass